HAE - Utang jangka dawa perusahaan Haemonetics Corp.

Haemonetics Corporation (HAE) is scaling sales of high-margin cartridges by implementing hospital blood collection systems. The company's long-term debt history demonstrates borrowing dynamics, where the 1.10 indicator expresses the state of the metric. Revenues are based on the supply of equipment and consumables for blood banks and surgery. Growth prospects rely on plasma demand and the development of the high-yield hemostasis segment.

This indicator aggregates total credit obligations with maturities exceeding one year, reflecting the company's long-term debt load and financial leverage. By analyzing the issuer's long-term liability statistics, investors assess the capital stability of Haemonetics Corporation (HAE), which is critical for maintaining its status as a global tech giant in safe blood transfusion and the development of innovative medical equipment.